Comparison
A side-by-side look at two recovery peptides that are often grouped together online.
BPC-157 has more public confusion; TB-500 claims often mix up product identity, fragments, and related molecules, so the exact substance matters.
Neither peptide has robust human efficacy evidence for tendon, ligament, or muscle recovery. BPC-157 has a few small human reports, while many TB-500 claims borrow from thymosin beta-4 or related fragments rather than testing the exact marketed product.
Neither is an FDA-approved recovery drug. BPC-157 also appears in FDA compounding-safety discussions, while TB-500 is especially vulnerable to name and sequence confusion. Those differences affect how much confidence a study can transfer to a product sold online.
The label must identify the exact peptide, sequence, formulation, and route. For injectable products, identity, concentration, sterility, endotoxin control, storage, and chain of custody matter as much as a headline purity percentage.
| Dimension | BPC-157 | TB-500 |
|---|---|---|
| Overall evidence grade | D | E |
| Evidence label | Limited human evidence | Evidence unclear |
| Regulatory status | Not FDA-approved for listed uses | Investigational / not approved |
| Editorial confidence | Low confidence | Low confidence |
| Efficacy | 1/5 limited | 0/5 not mapped |
| Safety | 1/5 limited | 1/5 limited |
| Regulatory risk | 4/5 high | 4/5 high |
| Product quality risk | 4/5 high | 5/5 very high |
| Primary claim categories | Injury recovery, Tendon and ligament claims, Gut and inflammation claims | Recovery claims, Soft-tissue claims, Performance claims |
BPC-157 has limited human evidence. The most useful sources are an oral trial registry, small human reports, review context, and FDA compounding concerns; the recovery protocol culture is much louder than the human data.
TB-500 is not interchangeable with full-length thymosin beta-4. Current evidence separates Ac-LKKTETQ identity and animal or in-vitro work from adjacent full-length thymosin beta-4 human trial records.
FDA. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee 2026.
Accessed 2026-07-24.
FDA meeting page for the July 23-24, 2026 PCAC review of BPC-157, KPV, TB-500, MOTs-C, emideltide/DSIP, Semax, and Epitalon bulk substances, including the uses evaluated for each, briefing documents, and docket FDA-2025-N-6895.
FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks 2026.
Accessed 2026-06-08.
FDA summarizes potential significant safety risks and missing safety information for several nominated peptide bulk substances.